Uncategorized
Assessing 4D Molecular Therapeutics: Insights From 5 Financial Analysts
Latest Ratings for FDMT Date Firm Action From To Jan 2022 SVB Leerink Initiates Coverage On Outperform Jan 2021 B of A Securities Initiates Coverage On Buy Jan 2021 Goldman Sachs Initiates Coverage On Neutral View More Analyst Ratings for FDMT View the Latest Analyst Ratings read more
Where Vulcan Materials Stands With Analysts
Latest Ratings for VMC Date Firm Action From To Feb 2022 Truist Securities Maintains Buy Jan 2022 Barclays Maintains Overweight Dec 2021 Barclays Maintains Overweight View More Analyst Ratings for VMC View the Latest Analyst Ratings read more
Expert Outlook: AbbVie Through The Eyes Of 4 Analysts
Latest Ratings for ABBV Date Firm Action From To Feb 2022 UBS Downgrades Buy Neutral Feb 2022 Mizuho Maintains Buy Feb 2022 Barclays Maintains Equal-Weight View More Analyst Ratings for ABBV View the Latest Analyst Ratings read more
Figma Shares Edge Higher After Explosive IPO Debut, Despite Valuation Concerns
Figma shares traded higher on Friday, continuing to draw investor attention after a volatile debut session on Thursday that saw the stock surge over 250% following its initial public offering. read more
